Drug Profile


Alternative Names: Metgluna

Latest Information Update: 08 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Elixir Pharmaceuticals
  • Class Antihyperglycaemics; Biguanides; Isoindoles
  • Mechanism of Action AMP activated protein kinase stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 08 Oct 2010 No development reported - Phase-III for Type-2 diabetes mellitus in USA (PO)
  • 21 Nov 2008 Final efficacy and safety data from a phase III trial Type-2 diabetes released by Elixir
  • 28 Mar 2008 Phase-III clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top